HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mead Johnson Looks City To City In Chinese Expansion Strategy

This article was originally published in The Tan Sheet

Executive Summary

A disciplined growth strategy enables Mead Johnson Nutrition to expand its footprint in China and other emerging markets, as lower U.S. birth rates continue to dampen the firm's domestic business.

You may also be interested in...

Sales & Earnings In Brief

P&G sees sign of North American recovery

Mead Johnson Expands Presence In Emerging Markets With Middle East JV

Mead Johnson Nutrition hopes strategic steps in developing markets - the latest a Middle East pediatric nutrition joint venture - will create a giant footprint for its infant formula products

Perrigo Grows Into Adjacent Infant Formula Category With PBM Acquisition

Perrigo takes the next step toward becoming a one-stop shop for private-label consumer health products with its $808 million acquisition of infant formula and baby food firm PBM Holdings Inc

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts